GlassScriptPhysician profile
Maryam Amini
NPI 1245402072
$2,134.44
in general payments reported to CMS, 2019-2025
29 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $358 · 2021: $148 · 2022: $287 · 2023: $472 · 2024: $219 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $348.18 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $232.94 | 2019-2022 | |
| Novo Nordisk INC | $229.33 | 2023-2025 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $181.91 | 2019-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $123.05 | 2019-2024 | |
| Medtronic, INC. | $105.27 | 2023 | Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.26 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.69 | 2023-2025 | Glassia, Hyqvia, Cuvitru |
| Mylan Specialty L.P. | $73.89 | 2020-2023 | Yupelri |
| Baxter Healthcare | $68.87 | 2022-2023 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $50.82 | 2024 | Inspire |
| Lilly USA, LLC | $50.30 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $48.47 | 2023-2025 | Tezspire |
| United Therapeutics Corporation | $46.34 | 2024-2025 | Tyvaso, Tyvaso |
| Janssen Pharmaceuticals, INC | $41.36 | 2023-2024 | Xarelto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.02 | 2022-2024 | Zerbaxa |
| Genzyme Corporation | $39.25 | 2020-2022 | |
| Grifols USA, LLC | $36.46 | 2022-2024 | Prolastin-C Liquid |
| Advanced Respiratory, INC | $36.44 | 2019-2020 | |
| Verona Pharma, INC. | $33.33 | 2025 | Ohtuvayre |
| Resmed Corp | $25.87 | 2025 | |
| Mallinckrodt Hospital Products INC. | $23.56 | 2024 | Terlivaz |
| Harmony Biosciences LLC | $23.50 | 2023 | Wakix |
| Novartis Pharmaceuticals Corporation | $22.78 | 2023 | |
| Vifor Pharma, INC. | $22.16 | 2025 | Zemaira |
| Circassia INC. | $19.05 | 2020 | |
| Electromed, INC. | $15.57 | 2025 | Smartvest |
| Pfizer INC. | $15.18 | 2020 | |
| Allergan, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Amini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.